Published in Cancer Treat Rep on April 17, 1980
Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A (1980) 1.26
Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Natl Acad Sci U S A (1984) 1.06
Biochemical enzyme analysis in acute leukaemia. J Clin Pathol (1985) 0.99
Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest (1984) 0.87
Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells. Proc Natl Acad Sci U S A (1982) 0.81
Evolution of the arabinosides and the pharmacology of fludarabine. Drugs (1994) 0.77
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique. Histochem J (1979) 4.06
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1987) 2.70
Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 2.38
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol (1995) 2.32
In vivo cultivation of tumor cells in hollow fibers. Life Sci (1995) 2.29
Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest (1991) 2.28
Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 2.24
Characterization of glass adherent human mononuclear cells. J Immunol (1973) 2.22
Allopurinol in the treatment of gout. Ann Intern Med (1966) 2.22
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 2.16
A comparison of the metabolic response to phagocytosis in human granulocytes and monocytes. J Clin Invest (1976) 2.10
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A (1978) 1.93
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia (2011) 1.55
Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest (1991) 1.55
Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest (1989) 1.53
Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res (1992) 1.49
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst (1995) 1.44
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res (1998) 1.42
Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J Biol Chem (1997) 1.42
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol (2002) 1.42
Aplastic anemia with platelet autoantibodies in a patient after taking methazolamide. Am J Ophthalmol (1990) 1.41
Cytotoxic alkaloids from Tylophora indica. Pharmazie (2001) 1.40
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia (2004) 1.38
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1994) 1.37
Association of terminal deoxynucleotidyl transferase with Ku. Proc Natl Acad Sci U S A (1999) 1.36
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res (1998) 1.33
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (2005) 1.32
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia (1994) 1.32
Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci (1987) 1.31
Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A (1979) 1.28
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia (2012) 1.24
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia (2003) 1.23
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood (1999) 1.23
Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res (2001) 1.22
Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. Science (1981) 1.21
Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A (1996) 1.20
The effect of sodium azide on the chemiluminescence of granulocytes--evidence for the generation of multiple oxygen radicals. J Lab Clin Med (1977) 1.16
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res (1997) 1.15
Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood (1998) 1.14
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst (1994) 1.14
The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J Nat Prod (1993) 1.13
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retroviruses (1997) 1.12
Localisation of immunoglobulin (IgG) within the rat metrial gland. J Reprod Immunol (1980) 1.11
Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol (1995) 1.10
CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood (1990) 1.10
Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci U S A (1991) 1.09
Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res (1992) 1.09
Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol (1998) 1.09
Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med (1986) 1.08
Proceedings: A quarter century with splenectomy. Changing concepts. Arch Surg (1974) 1.08
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia (2011) 1.07
An added dimension: will three-dimensional cultures improve our understanding of drug resistance? J Natl Cancer Inst (1994) 1.07
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood (2000) 1.07
The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood (1981) 1.06
Immune thrombocytopenic purpura. Med Clin North Am (1980) 1.06
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol (1998) 1.06
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia (2012) 1.05
ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A (1980) 1.04
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 1.03
Bordetella bronchiseptica pneumonia in a patient with chronic lymphocytic leukemia. South Med J (1987) 1.03
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol (2012) 1.03
Decreased serum B 12 levels with oral contraceptive use. JAMA (1972) 1.03
Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose. Am J Respir Crit Care Med (1997) 1.01
An improved composition for embalming fluid to preserve cadavers for anatomy teaching in the United Kingdom. J Anat (1993) 1.01
Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest (2000) 1.01
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer (2001) 1.00
Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. J Biol Chem (1987) 1.00
Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med (1996) 0.99
Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. J Clin Invest (1983) 0.99
Concomitant adsorption and stability of some anthracycline antibiotics. J Pharm Sci (1982) 0.98
Adriamycin and daunomycin generate reactive oxygen compounds in erythrocytes. Blood (1978) 0.98
Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Cancer Res (1990) 0.96
Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. J Biol Chem (1989) 0.96
Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. J Clin Invest (1979) 0.96
Z-nucleotide accumulation in erythrocytes from Lesch-Nyhan patients. J Clin Invest (1985) 0.96
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs (1990) 0.95
Quantitation of the nucleophosmin/B23-translocation using imaging analysis. Cancer Lett (1996) 0.95
Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol (1994) 0.94
Relationship of glucose oxidation to aggregation of human platelets. Blood (1973) 0.94
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer (1989) 0.93
Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. J Biol Chem (1995) 0.93